<DOC>
	<DOCNO>NCT00259987</DOCNO>
	<brief_summary>This Phase II study ass efficacy , safety , pharmacodynamics pharmacokinetics 1000 mg 1500 mg lapatinib administer daily patient relapse adenocarcinoma esophagus , include tumor GE junction gastric cardia .</brief_summary>
	<brief_title>Effects Of Lapatinib ( GW572016 ) In Patients With Relapsed Adenocarcinoma Of The Esophagus</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Inclusion criterion : Has histologically confirm adenocarcinoma esophagus . GE ( gastroesophageal ) junction gastric cardia . Must nonchildbearing potential childbearing potential . Have negative serum pregnancy test agree approve form birth control . Have ECOG ( Eastern Cooperative Oncology Group ) Performance status less equal 2 . Have life expectancy least 12 week . Have provide write informed consent . Investigator consider patient fit study lab test result interview . Exclusion criterion : Pregnant lactate female . Prior resection small bowel . Received major surgery . Received prior radiation therapy mediastinum abdomen . Has know immediate delay hypersensitivity reaction . Idiosyncrasy drug chemically relate study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>relapse adenocarcinoma</keyword>
	<keyword>esophagus</keyword>
	<keyword>tumor</keyword>
	<keyword>GE junction</keyword>
	<keyword>cancer</keyword>
	<keyword>lapatinib</keyword>
	<keyword>gastric cardia</keyword>
</DOC>